Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LFHP-1c (Univ. of Kansas Medical Center)
- Development stage
- Preclinical
- Lead developer
- University of Kansas Medical Center
- Modality
- Small Molecules
01
Overview
LFHP-1c (Univ. of Kansas Medical Center): sourced facts only. name: "Pharmacological inhibition of PGAM5 using a novel small molecule-based modulator LFHP-1c (3 mg/kg BW, subcutaneous) at 24 hours post irradiation mitigates gastrointestinal toxicity." [DOI:10.1158/1538-7445.am2026-4628]; target: "Pharmacological inhibition of PGAM5 using a novel small molecule-based modulator LFHP-1c (3 mg/kg BW, subcutaneous) at 24 hours post irradiation mitigates gastrointestinal toxicity." [DOI:10.1158/1538-7445.am2026-4628]; developer: "University of Kansas Medical Center, Kansas City, KS." [DOI:10.1158/1538-7445.am2026-4628]; modality: "Pharmacological inhibition of PGAM5 using a novel small molecule-based modulator LFHP-1c (3 mg/kg BW, subcutaneous) at 24 hours post irradiation mitigates gastrointestinal toxicity." [DOI:10.1158/1538-7445.am2026-4628]; stage: "Mice exposed to partial body irradiation (PBI) with 2.5% bone marrow shielding (LD100/15) followed by LFHP-1c treatment demonstrated significant improvement of mice survival (90% mice survived beyond 30 day) (p< 0.00002) compared to irradiated control where all the mice died within 14 days." [DOI:10.1158/1538-7445.am2026-4628]
02
Targets
PGAM5 (Phosphoglycerate mutase 5)
Beyond the preview
Go deeper on LFHP-1c (Univ. of Kansas Medical Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LFHP-1c (Univ. of Kansas Medical Center).